{
    "nct_id": "NCT05081479",
    "official_title": "Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma",
    "inclusion_criteria": "* Patients must be 18 years of age or older\n* Patients who will receive axicabtagene ciloleucel for treatment of lymphoma\n* Patients must have adequate end organ function to be eligible for this study as defined by the following criteria:\n\n  * ECOG performance status 0-2\n  * Hematologic function with ANC ≥ 1000, Hgb ≥ 8, Plt ≥ 50k unless there is disease related hematologic toxicity\n  * Renal function with CrCr ≥ 40 ml/min or Cr ≤ 1.5 x ULN\n  * Hepatic function with ALT/AST ≤ 2.5 x ULN, TBili ≤ 1.5 x ULN.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with known allergy to N-AC",
    "miscellaneous_criteria": ""
}